MedPage Today September 14, 2023
— They argue that the government is using coercion while claiming sellers have options
Experts debated the claims made by drug companies and industry allies suing the federal government over its recently launched drug price negotiation program during an online panel discussion hosted by KFF on Tuesday.
At issue is whether the federal government is “coercing” companies into making their drugs available at lower-than-market prices, explained Dan Troy, JD, managing director at the Berkeley Research Group, who currently serves on the litigation counsel advisory board for the U.S. Chamber of Commerce, one of the groups suing.
“The bottom line is this is not a price negotiation. These are price controls by other names,” argued Troy, who is not involved in...
Today's Sponsors
Today's Sponsor